Pharma BD Deal Intelligence

GlaxoSmithKline plc / Genmab A/S (HuMax-TAC follow-on)

2009 · Licensing/Option · $102M · Complete

Original ofatumumab Dec 2006; total deal up to $2.1B in 2009 amendments. Source: GSK, Genmab filings. NOTE: original signing 2006 — listing 2009 amendment iteration if applicable.

Key facts

• Announced May 21, 2009
• Deal value $102M
• Deal type Licensing/Option

← Browse all deals  ·  How we score deals